Ionis-AstraZeneca CARDIO-TTRansform misses primary endpoint in ATTR-CM
Jul 9, 2026, 2:06 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Primary endpoint miss in a large Phase 3 trial creates immediate downside pressure, especially with stabilizer effects clouding interpretation. However, safety profile and secondary signals may limit downside and support upside if ESC data or additional analyses point to future opportunities or patient subgroups. Similar past biotech results show initial selloffs followed by recovery if investors focus on long-term value and pipeline breadth.
AI summary
What happened, with direct paths to the underlying reporting
Ionis and AstraZeneca announced that CARDIO-TTRansform did not meet the primary endpoint in ATTR-CM, though a prespecified monotherapy subgroup showed a nominal benefit. Safety remained favorable, with large, balanced trial enrollment (1,432 participants) and substantial use of stabilizers at baseline. ESC data presentation in August 2026 could influence the treatment landscape and future perceptions of eplontersen's value, while Ionis reiterates cash-flow breakeven by 2028.
CARDIO-TTRansform Phase 3 miss primary endpoint; monotherapy shows nominal benefit.
Safety profile remains favorable; tolerability consistent with prior results.
Trial enrolled 1,432 patients across 130 sites in 20 countries; Week 140 endpoint.
57% on stabilizers at baseline; 24% initiated stabilizers during the trial.
Results to be presented at ESC Congress in August 2026; long-term value unaffected by single trial.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Ionis surged as it inked a global licensing deal with Recordati for Zilganersen outside the U.S., while Tryngolza received FDA clearance with a July U.S. launch potential. The com…
Ionis Pharmaceuticals has revised the wholesale acquisition cost for its drug Tryngolza to $40,000, effective April 1, in anticipation of FDA approval for sHTG by June 30. This st…
Ionis Pharmaceuticals reported a Q4 adjusted loss of $1.15, surpassing Wall Street's estimate of $1.32. This better-than-expected performance may positively influence investor sen…
Olezarsen reduces fasting triglyceride levels by up to 72%. 85% reduction in acute pancreatitis events observed with olezarsen. 86% of patients achieved triglyceride levels below…
